Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models

Emily S. Van Laar, Steven D Weitman, John R. MacDonald, Stephen J. Waters

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND. Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines. METHODS. To elucidate the activity of irofulven monotherapy and in combination, PC-3 and DU-145 cell lines were utilized in cellular viability assessments and tumor growth inhibition studies. RESULTS. Viability assays with irofulven and mitoxantrone show additive to synergistic activity. Furthermore, irofulven and mitoxantrone in combination exhibit enhanced antitumor activity against PC-3 and DU-145 xenografts. Additive combination effects are also observed when irofulven and docetaxel were tested against PC-3 xenografts and curative activity (8/10 CR) is observed in DU-145 xenografts. CONCLUSIONS. These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)22-32
Number of pages11
JournalProstate
Volume59
Issue number1
DOIs
StatePublished - Apr 1 2004

Fingerprint

docetaxel
Mitoxantrone
Prostatic Neoplasms
Heterografts
Androgens
irofulven
Hormones
Cell Line

Keywords

  • DU-145
  • HMAF
  • PC-3
  • Preclinical

ASJC Scopus subject areas

  • Urology

Cite this

Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models. / Van Laar, Emily S.; Weitman, Steven D; MacDonald, John R.; Waters, Stephen J.

In: Prostate, Vol. 59, No. 1, 01.04.2004, p. 22-32.

Research output: Contribution to journalArticle

Van Laar, Emily S. ; Weitman, Steven D ; MacDonald, John R. ; Waters, Stephen J. / Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models. In: Prostate. 2004 ; Vol. 59, No. 1. pp. 22-32.
@article{82d10082a62947148e6bea4e9506802c,
title = "Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models",
abstract = "BACKGROUND. Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines. METHODS. To elucidate the activity of irofulven monotherapy and in combination, PC-3 and DU-145 cell lines were utilized in cellular viability assessments and tumor growth inhibition studies. RESULTS. Viability assays with irofulven and mitoxantrone show additive to synergistic activity. Furthermore, irofulven and mitoxantrone in combination exhibit enhanced antitumor activity against PC-3 and DU-145 xenografts. Additive combination effects are also observed when irofulven and docetaxel were tested against PC-3 xenografts and curative activity (8/10 CR) is observed in DU-145 xenografts. CONCLUSIONS. These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer.",
keywords = "DU-145, HMAF, PC-3, Preclinical",
author = "{Van Laar}, {Emily S.} and Weitman, {Steven D} and MacDonald, {John R.} and Waters, {Stephen J.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1002/pros.10351",
language = "English (US)",
volume = "59",
pages = "22--32",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Antitumor Activity of Irofulven Monotherapy and in Combination with Mitoxantrone or Docetaxel Against Human Prostate Cancer Models

AU - Van Laar, Emily S.

AU - Weitman, Steven D

AU - MacDonald, John R.

AU - Waters, Stephen J.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - BACKGROUND. Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines. METHODS. To elucidate the activity of irofulven monotherapy and in combination, PC-3 and DU-145 cell lines were utilized in cellular viability assessments and tumor growth inhibition studies. RESULTS. Viability assays with irofulven and mitoxantrone show additive to synergistic activity. Furthermore, irofulven and mitoxantrone in combination exhibit enhanced antitumor activity against PC-3 and DU-145 xenografts. Additive combination effects are also observed when irofulven and docetaxel were tested against PC-3 xenografts and curative activity (8/10 CR) is observed in DU-145 xenografts. CONCLUSIONS. These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer.

AB - BACKGROUND. Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines. METHODS. To elucidate the activity of irofulven monotherapy and in combination, PC-3 and DU-145 cell lines were utilized in cellular viability assessments and tumor growth inhibition studies. RESULTS. Viability assays with irofulven and mitoxantrone show additive to synergistic activity. Furthermore, irofulven and mitoxantrone in combination exhibit enhanced antitumor activity against PC-3 and DU-145 xenografts. Additive combination effects are also observed when irofulven and docetaxel were tested against PC-3 xenografts and curative activity (8/10 CR) is observed in DU-145 xenografts. CONCLUSIONS. These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer.

KW - DU-145

KW - HMAF

KW - PC-3

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=1642308705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642308705&partnerID=8YFLogxK

U2 - 10.1002/pros.10351

DO - 10.1002/pros.10351

M3 - Article

C2 - 14991863

AN - SCOPUS:1642308705

VL - 59

SP - 22

EP - 32

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -